A Once-Daily Pill for Pancreatic Cancer Just Won Approval, and It Nearly Doubled Survival in Trial

FDA approved Rasonque for metastatic pancreatic adenocarcinoma. A phase 3 trial found median survival of 13.2 months against 6.7 on chemotherapy.

Have A Referral?